1型糖尿病绝经前女性多囊卵巢综合征及相关高雄激素特征的患病率:系统综述与Meta分析
该系统综述与Meta分析纳入19项研究、共1042例1型糖尿病绝经前女性,汇总显示多囊卵巢综合征(PCOS)患病率约26%(95%CI 19-34%),经典PCOS为16%(95%CI 10-22%),高雄激素型PCOS为26%(95%CI 16-41%),多毛、高雄激素血症、稀发月经和卵巢多囊形态也较常见。
要点
- 1型糖尿病绝经前女性中PCOS汇总患病率约26%(95%CI 19-34%)。
- 按美国国立卫生研究院标准的经典PCOS汇总患病率为16%(95%CI 10-22%)。
- 多毛、高雄激素血症、稀发月经和卵巢多囊形态的患病率分别为24%、29%、24%和34%。
核心结论
- 该系统综述与Meta分析显示,约每4例1型糖尿病绝经前女性中就有1例存在PCOS或相关高雄激素特征。
- 需要更大规模的研究来确认这一关联,并探讨不同变量对PCOS发生的影响。
研究设计与样本
- 系统综述与Meta分析,检索Medline-OVID和Embase数据库,截至2021年3月29日发表的横断面或前瞻性研究。
- 纳入19项研究、共1042例1型糖尿病绝经前女性,报告PCOS和/或相关高雄激素特征的患病率。
- 采用专门评估人群患病率研究的工具评价偏倚风险,12项研究为低风险,其余7项为中等风险。
主要发现
- 考虑所有可能表型时(ESHRE-美国生殖医学学会标准),1型糖尿病女性PCOS汇总患病率为26%(95%CI 19-34%;13项研究,684例女性)。
- 经典PCOS(美国国立卫生研究院标准)汇总患病率为16%(95%CI 10-22%;9项研究,614例女性)。
- 高雄激素型PCOS(雄激素过多与PCOS学会标准)汇总患病率为26%(95%CI 16-41%;5项研究,329例女性)。
- 多毛患病率24%,高雄激素血症29%,稀发月经24%,卵巢多囊形态34%。
- 几乎所有这些Meta分析的异质性均较高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 几乎所有这些Meta分析的异质性均较高。
- 需要更大规模的研究来确认这一关联,并探讨不同变量对PCOS发生的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An increased prevalence of functional hyperandrogenism-including polycystic ovary syndrome (PCOS)-has been described in women with type 1 diabetes (T1D). However, heterogeneity between studies is frequent, and prevalence rates vary according to different criteria used for the diagnosis of PCOS and the population studied. OBJECTIVE AND RATIONALE: We aimed to perform a systematic review and meta-analysis of the prevalence of PCOS and related hyperandrogenic traits in premenopausal women with T1D. This way, we intend to increase the precision of the estimates of prevalence of PCOS and related traits in women with T1D, and to explore sources of heterogeneity while providing prevalence estimates for clinically relevant subgroups such as the different phenotypes. SEARCH METHODS: We conducted a systematic review of the literature using Medline-OVID and Embase databases (Open Science Framework registry for systematic review protocols, https://osf.io/6cv9p/). Studies published up to 29 March 2021 were considered. We selected cross-sectional or prospective studies that reported, in patients with T1D, prevalence data on PCOS according to current definitions and different phenotypes, and/or prevalence rates of other related traits (hirsutism, hyperandrogenaemia, oligo-amenorrhoea and/or polycystic ovarian morphology: PCOM). Exclusion criteria for the review were studies addressing types of diabetes other than T1D; and studies using diagnostic definitions of PCOS different than those mentioned above. Two independent researchers performed data extraction. To assess the risk of bias, we used a tool developed specifically to appraise population-based prevalence studies. OUTCOMES: We selected 19 studies (1042 women) reporting the prevalence of PCOS and/or other hyperandrogenic traits. Regarding bias, 12 studies were considered of low-risk, and the remaining seven studies were considered intermediate risk. The pooled prevalence of PCOS when considering all possible phenotypes (ESHRE- American Society for Reproductive Medicine criteria) in T1D was 26% (95% CI: 19-34%; 13 studies, 684 women). Pooled prevalence of classic PCOS (US National Institutes of Health criteria) was 16% (95% CI: 10-22%; 9 studies, 614 women). Pooled prevalence of hyperandrogenic PCOS (Androgen Excess and PCOS Society criteria) was 26% (95% CI: 16-41%; 5 studies, 329 women). Hirsutism (24%), hyperandrogenaemia (29%), oligomenorrhoea (24%) and PCOM (34%) were also prevalent. Heterogeneity was high in almost all these meta-analyses. WIDER IMPLICATIONS: This systematic review and meta-analysis showed that PCOS and related hyperandrogenic traits are present in approximately one in every four women with T1D. Larger studies are needed to confirm this association, to address the effect of different variables on the occurrence of PCOS.
引用
- Bayona A, Martínez-Vaello V, Zamora J, et al. Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis. Hum Reprod Update. 2022. PMID: 35237802. doi:10.1093/humupd/dmac011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。